Peptides for muscle growth: what the evidence shows

Peptides for muscle growth can raise growth hormone or IGF-1, but that is not the same as building meaningful, lasting muscle in people. Human body-composition evidence is thin: MK-677 has increased fat-free mass without improving strength, while CJC-1295, ipamorelin, IGF-1, and follistatin claims lean heavily on hormones, mechanisms, or non-bodybuilding research.

Which muscle building peptides get sold for this goal?

The main muscle building peptides sold online fall into three buckets: compounds that trigger growth-hormone release, IGF-1 analogues that act farther down the same pathway, and follistatin products meant to loosen the body’s brake on muscle growth. The category name is chemically sloppy—MK-677 is a small molecule, while follistatin is a much larger protein—but it reflects how the products are marketed.

• CJC-1295 copies part of growth-hormone-releasing hormone and tells the pituitary to release more growth hormone.
• Ipamorelin activates the ghrelin receptor and produces a short growth-hormone pulse.
• MK-677 (ibutamoren) activates that receptor orally. MK-677 is not a peptide, despite routinely appearing on peptide-store menus.
• IGF-1 LR3 is a modified, longer-acting IGF-1 analogue sold mainly as a research chemical.
• Follistatin binds proteins including myostatin, a signal that restrains muscle growth.

The first three sit in the growth-hormone peptide family. The plain-English guide to growth-hormone secretagogues explains how that class differs from taking growth hormone itself.

Does raising GH or IGF-1 build muscle?

Raising growth hormone (GH) or insulin-like growth factor 1 (IGF-1) proves that a compound reaches its hormonal target; it does not prove hypertrophy, strength, or a physique change. Think of the hormone result as hearing the starter motor turn. The useful outcome is whether the engine moves the car, measured here as muscle size, strength, function, and persistence after treatment.

A randomized study found that CJC-1295 raised mean GH and IGF-1 for days in healthy adults. It did not test muscle gain. An eight-person-per-dose study found that ipamorelin produced a brief GH pulse; it did not measure hypertrophy or strength. Those are real human pharmacology results attached to a bodybuilding outcome that human trials have not established.

What does the MK-677 muscle evidence show?

MK-677 has the best direct human body-composition result in this group, but the result is narrower than “builds muscle.” In a randomized trial of 65 healthy adults aged 60 to 81, fat-free mass rose by 1.1 kg with MK-677 and fell by 0.5 kg with placebo after one year. Strength and physical function did not improve.

The MK-677 trial also found no significant reduction in total or visceral fat. Body weight increased more with MK-677, fasting glucose rose by an average of 5 mg/dL, and insulin sensitivity fell. Fat-free mass includes water as well as muscle tissue, so a scan moving upward cannot by itself settle how much new contractile muscle was built. The study involved older adults, not trained bodybuilders, and its two-year exploratory analysis did not turn the lean-mass change into a functional win.

What about IGF-1 and follistatin for bodybuilding?

IGF-1 and follistatin have powerful muscle-growth logic, but the products sold for bodybuilding outrun their human evidence. Native recombinant IGF-1, called mecasermin, is a prescription drug for a narrow pediatric growth-failure indication—not an approval of IGF-1 LR3 for adults. Follistatin has reached small human gene-therapy studies, but gene delivery into diseased muscle is not evidence for an injected research-market peptide.

The DailyMed label for mecasermin covers children with severe primary IGF-1 deficiency and carries hypoglycemia and other serious warnings. IGF-1 LR3 itself lacks human muscle-building trials. In a six-patient Becker muscular dystrophy study, researchers delivered a follistatin gene directly into both quadriceps; some walking results improved and others did not. That early follistatin gene-therapy trial cannot tell us whether an online follistatin vial adds muscle in a healthy lifter.

Are peptides for bodybuilding approved or well studied for safety?

The compounds discussed here are not FDA-approved as bodybuilding treatments, and long-term safety evidence in healthy lifters is missing. Raising the GH/IGF-1 axis can bring water retention, tingling, joint or muscle discomfort, higher blood sugar, and lower insulin sensitivity. Direct IGF-1 activity adds a serious low-blood-sugar risk. Product identity, purity, and sterility create a separate uncertainty.

FDA has specifically said that compounded CJC-1295 may pose immunogenicity and impurity-characterization risks, and that available clinical data are limited. The agency raises similar concerns for ipamorelin and says it lacks enough information to know whether certain injectable routes would cause harm. Those details appear in the FDA’s compounding safety-risk review. “Research use only” is not a quiet synonym for approved medicine.

How should you judge claims about peptides for muscle growth?

Judge peptides for muscle growth by the endpoint actually measured. A GH spike is hormone evidence. A higher fat-free-mass reading is body-composition evidence. Larger muscle fibers are hypertrophy evidence. More weight on the bar is strength evidence. Those findings can point in the same direction, but they are not interchangeable—and lasting gains after the compound stops are a further question again.

That distinction keeps both hype and reflexive dismissal out of the way. CJC-1295 and ipamorelin clearly affect GH signaling; MK-677 has a human lean-mass signal; IGF-1 and follistatin remain biologically credible research directions. The claim that any of them reliably produces meaningful, durable muscle gain in healthy bodybuilders is still ahead of the data. The evidence-grading guide shows how to sort each claim by the rung it has actually reached.